Jazz Pharmaceuticals plc – (JAZZ) Given Daily Media Sentiment Rating of 0.29
Headlines about Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) have trended positive this week, Alpha One Sentiment Analysis reports. The research group, a unit of Accern, ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Jazz Pharmaceuticals plc – earned a media sentiment score of 0.29 on Alpha One’s scale. Alpha One also gave media headlines about the specialty pharmaceutical company an impact score of 92 out of 100, indicating that recent news coverage is extremely likely to have an impact on the company’s share price in the next few days.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 0.89% during midday trading on Friday, hitting $152.84. The stock had a trading volume of 436,725 shares. The firm has a market cap of $9.13 billion, a price-to-earnings ratio of 23.84 and a beta of 1.22. The firm has a 50 day moving average of $143.48 and a 200 day moving average of $123.54. Jazz Pharmaceuticals plc – has a 52 week low of $95.80 and a 52 week high of $160.00.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last posted its earnings results on Tuesday, February 28th. The specialty pharmaceutical company reported $1.91 earnings per share for the quarter, missing analysts’ consensus estimates of $2.65 by $0.74. The firm earned $396.62 million during the quarter, compared to the consensus estimate of $398.91 million. Jazz Pharmaceuticals plc – had a net margin of 24.81% and a return on equity of 30.50%. The firm’s revenue was up 16.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.60 EPS. Equities research analysts predict that Jazz Pharmaceuticals plc – will post $11.10 EPS for the current year.
A number of brokerages recently issued reports on JAZZ. Vetr cut Jazz Pharmaceuticals plc – from a “strong-buy” rating to a “hold” rating and set a $157.46 target price on the stock. in a report on Thursday, April 6th. Leerink Swann set a $170.00 target price on Jazz Pharmaceuticals plc – and gave the stock a “buy” rating in a report on Thursday, April 6th. Deutsche Bank AG set a $176.00 target price on Jazz Pharmaceuticals plc – and gave the stock a “buy” rating in a report on Thursday, April 6th. Cowen and Company reiterated an “outperform” rating and issued a $190.00 target price on shares of Jazz Pharmaceuticals plc – in a report on Friday, April 7th. Finally, Cantor Fitzgerald increased their target price on Jazz Pharmaceuticals plc – from $189.00 to $197.00 and gave the stock an “overweight” rating in a report on Friday, April 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the company. Jazz Pharmaceuticals plc – has a consensus rating of “Buy” and an average target price of $181.23.
In other Jazz Pharmaceuticals plc – news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction dated Tuesday, April 11th. The stock was sold at an average price of $152.12, for a total value of $152,120.00. Following the completion of the sale, the chief executive officer now owns 308,491 shares in the company, valued at $46,927,650.92. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction dated Monday, April 17th. The stock was sold at an average price of $152.56, for a total value of $30,512.00. Following the completion of the sale, the senior vice president now owns 22,562 shares of the company’s stock, valued at approximately $3,442,058.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,942 shares of company stock valued at $2,098,147. Company insiders own 3.90% of the company’s stock.
About Jazz Pharmaceuticals plc –
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.